Literature DB >> 17089499

Visceral leishmaniasis in northern Ethiopia.

T Haile1, S D Anderson.   

Abstract

BACKGROUND: Visceral leishmaniasis (VL) has been well documented by the Medecins sans Frontieres (MSF) VL treatment programmeme in the Tigray region of Ethiopia, but reports are limited from other facilities in this region where this disease continues to cause substantial morbidity and mortality.
OBJECTIVE: To describe the clinical manifestations and treatment outcomes of VL in a government hospital in Axum, Ethiopia.
DESIGN: Retrospective analysis of 111 patients treated for visceral leishmaniasis.
SETTING: Saint Mary's Hospital, Axum, Ethiopia.
SUBJECTS: One hundred and Eleven patients treated for visceral leishmaniasis in a government hospital in Axum, Ethiopia.
RESULTS: All patients were male and most reported travel history to Humera, a known endemic area. Patients presented with classic signs and symptoms, including fever, weight loss, splenomegaly and anaemia. Almost one third (15/53) of patients who underwent HIV testing had a positive result. Crude death rate at six months was 13.5 per 100 patients (95% CI: 6.7 - 20.3 per 100 patients). Presence of HIV and other co-infections were associated with increased risk of death.
CONCLUSIONS: Clinical manifestations and treatment outcomes in this setting were comparable to that of the MSF programmeme in Tigray, Ethiopia and highlight the importance of HIV testing for patients presenting with visceral leishmaniasis.

Entities:  

Mesh:

Year:  2006        PMID: 17089499     DOI: 10.4314/eamj.v83i7.9451

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  8 in total

1.  Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia.

Authors:  Tesfaye Gelanew; Zewdu Hurissa; Ermias Diro; Aysheshm Kassahun; Katrin Kuhls; Gabriele Schönian; Asrat Hailu
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Update on research and activities at the Centers for Disease Control and Prevention, and the agency for toxic substances and disease registry.

Authors:  Richard Kleiman; E Danielle Rentz; Eyasu Teshale; Nicola Thompson; Helen Schurz-Rogers
Journal:  J Med Toxicol       Date:  2008-09

Review 3.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

4.  Risk factors of visceral leishmaniasis: a case control study in north-western Ethiopia.

Authors:  Solomon Yared; Kebede Deribe; Araya Gebreselassie; Wessenseged Lemma; Essayas Akililu; Oscar D Kirstein; Meshesha Balkew; Alon Warburg; Teshome Gebre-Michael; Asrat Hailu
Journal:  Parasit Vectors       Date:  2014-10-14       Impact factor: 3.876

Review 5.  Visceral leishmaniasis in Ethiopia: an evolving disease.

Authors:  Samson Leta; Thi Ha Thanh Dao; Frehiwot Mesele; Gezahegn Alemayehu
Journal:  PLoS Negl Trop Dis       Date:  2014-09-04

6.  Population dynamics and habitat preferences of Phlebotomus orientalis in extra-domestic habitats of Kafta Humera lowlands--kala azar endemic areas in Northwest Ethiopia.

Authors:  Wossenseged Lemma; Habte Tekie; Meshesha Balkew; Teshome Gebre-Michael; Alon Warburg; Asrat Hailu
Journal:  Parasit Vectors       Date:  2014-08-06       Impact factor: 3.876

7.  Analysis of genetic polymorphisms and tropism in East African Leishmania donovani by Amplified Fragment Length Polymorphism and kDNA minicircle sequencing.

Authors:  Hanan T Jaber; Asrat Hailu; Francine Pratlong; Patrick Lami; Patrick Bastien; Charles L Jaffe
Journal:  Infect Genet Evol       Date:  2018-07-19       Impact factor: 3.342

8.  Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.

Authors:  Eyob Alemayehu Gebreyohannes; Akshaya Srikanth Bhagvathula; Tadesse Melaku Abegaz; Mohammed Assen Seid
Journal:  Infect Dis Poverty       Date:  2018-10-19       Impact factor: 4.520

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.